(VIANEWS) – Shares of DBV TECHNOLOGIES (CAC 40: DBV.PA) rose by a staggering 11.03% to €3.14 at 13:54 EST on Monday, following the last session’s upward trend. CAC 40 is rising 0.33% to €7,372.56, after two sequential sessions in a row of gains. This seems, up until now, a somewhat bullish trend trading session today.
DBV TECHNOLOGIES’s last close was €2.83, 48.39% below its 52-week high of €5.48.
About DBV TECHNOLOGIES
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Earnings Per Share
As for profitability, DBV TECHNOLOGIES has a trailing twelve months EPS of €-0.98.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -42.99%.
Moving Average
DBV TECHNOLOGIES’s value is way higher than its 50-day moving average of €2.79 and way below its 200-day moving average of €3.53.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 21.7% and 16.7%, respectively.
More news about DBV TECHNOLOGIES (DBV.PA).
